11beta-HSD inhibitors (AstraZeneca)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Name11beta-HSD inhibitors (AstraZeneca)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCorticosteroid 11-beta-dehydrogenase isozyme 1 inhibitors
TargetsCorticosteroid 11-beta-dehydrogenase isozyme 1
Therapy Area/IndicationsMetabolic SyndromeDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsMetabolic SyndromeDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A